Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

33.97 +0.05 (+0.15%)

Streaming Delayed Price Updated: 1:14 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong ↗

July 29, 2025

Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition.

Via Benzinga

A Glimpse of Teva Pharmaceutical Indus's Earnings Potential ↗

July 29, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters ↗

July 18, 2025

Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years.

Via The Motley Fool

Topics Artificial Intelligence

10 Health Care Stocks Whale Activity In Today's Session ↗

July 15, 2025

Via Benzinga

How Do Investors Really Feel About Teva Pharmaceutical Indus? ↗

June 05, 2025

Via Benzinga

Where Teva Pharmaceutical Indus Stands With Analysts ↗

May 28, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Looking Into Teva Pharmaceutical Indus's Recent Short Interest ↗

July 10, 2025

Via Benzinga

What Analysts Are Saying About Teva Pharmaceutical Indus Stock ↗

June 26, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys? ↗

June 25, 2025

Via The Motley Fool

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters ↗

June 16, 2025

Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.

Via The Motley Fool

Topics Artificial Intelligence Economy

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? ↗

June 06, 2025

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.

Via Benzinga

9 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2025

Via Benzinga

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030 ↗

May 29, 2025

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.

Via Benzinga

Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead ↗

May 28, 2025

Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter.

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Why Is Teva Stock Trading Higher On Tuesday? ↗

May 27, 2025

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Via Benzinga

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today ↗

May 12, 2025

Via The Motley Fool

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗

May 12, 2025

Via Benzinga

This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

May 12, 2025

Via Benzinga

Why Teva Pharmaceutical Stock Is Soaring Today ↗

May 07, 2025

Via The Motley Fool

Topics Earnings Stocks

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum ↗

May 07, 2025

Teva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations.

Via Benzinga

Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report ↗

May 07, 2025

Teva stock jumped early Wednesday after the drugmaker hiked its 2025 profit outlook, though trimmed its sales forecast.

Via Investor's Business Daily

Topics Government

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target ↗

May 06, 2025

Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.

Via Benzinga

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? ↗

May 05, 2025

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.

Via Benzinga

What Does the Market Think About Teva Pharmaceutical Indus? ↗

April 30, 2025

Via Benzinga

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now ↗

April 21, 2025

Short-term uncertainty has led to a golden opportunity for long-term investors.

Via The Motley Fool

Topics Economy Government Stocks

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility ↗

April 13, 2025

Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.

Via The Motley Fool

Topics Government Stocks World Trade

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now ↗

March 28, 2025

Via The Motley Fool

Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks ↗

March 24, 2025

Duquesne Family Office's chief is dumping shares of Wall Street's hottest artificial intelligence (AI) stocks in favor of a trio of companies that are righting their respective ships.

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

Starting at $3.75/week.

Subscribe Today